Citiustech Establishes New Technology Center In Rochester, Mn

IMT News Desk
IMT News Desk
· 2 min read

CitiusTech, a provider of healthcare technology services and solutions announced the opening of its new technology center in Rochester, MN – a city recognized for world-class healthcare. The new technology center follows closely on the heels of opening new centers in Mumbai, India and Dubai, UAE.

“Considering the strategic importance of the US market, CitiusTech is strengthening its presence in North America. Addition of the Rochester facility will allow us to serve our customers more effectively.” said Rizwan Koita, Chief Executive Officer of CitiusTech.

CitiusTech has now expanded its focus on the provider market to help them drive innovation in care delivery. With its enhanced solutions around new technologies (analytics, big data, mobile, cloud, etc.) and specialized technology practices, CitiusTech enables large health systems and IDNs to drive their key strategic areas—application development and validation, data integration and data management, clinical quality and performance management, and mobile and patient engagement—and improve business performance.

CitiusTech’s BI-Clinical is the most widely deployed third party healthcare BI/ analytics platform, certified for both provider and payer markets. BI-Clinical is deployed over 4,500+ locations, supporting over 550,000 providers and over 30 million lives. BI-Clinical has the largest measure library with 600+ pre-built KPIs including coverage of federal and commercial initiatives. BI-Clinical’s Rules Management Module (RMM) enables providers to build and manage quality measures and other rules (cohorts and alerts) in a highly configurable and auditable manner.

CitiusTech has grown significantly over the past five years. CitiusTech has revenues of over USD 100 million and is ranked amongst the top 100 healthcare IT companies in 2016 HCI 100 by Healthcare Informatics.

 

 

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk